Allakos - ALLK Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings or view top-rated stocks.

4 brokerages have issued 12-month target prices for Allakos' shares. Their ALLK share price forecasts range from $8.00 to $13.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts price targets for ALLK or view top-rated stocks among Wall Street analysts.

Allakos' stock was trading at $8.42 at the beginning of the year. Since then, ALLK stock has decreased by 11.0% and is now trading at $7.49.
View the best growth stocks for 2023 here.

Allakos saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 2,810,000 shares, a drop of 5.7% from the December 31st total of 2,980,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is presently 2.6 days. Currently, 6.0% of the company's shares are sold short.
View Allakos' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ALLK earnings forecast.

Allakos Inc. (NASDAQ:ALLK) released its earnings results on Monday, November, 7th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.25.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.14%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends.

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLK stock can currently be purchased for approximately $7.49.

Allakos (NASDAQ:ALLK) has a market capitalization of $638.15 million. The company earns $-269,860,000.00 in net income (profit) each year or ($6.76) on an earnings per share basis.

The company employs 192 workers across the globe.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.